Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

A new COVID-19 variant, NB.1.8.1, has spread in the Mediterranean, Southeast Asia, and Western Pacific regions.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

AI can determine eczema severity from images, with results correlating with severity assigned by board-certified clinicians.

The FDA has announced its plan for systematically reviewing food additives already commercially available for the first time.

Those who are not considered "high risk" will be ineligible for future COVID-19 booster vaccines that have not undergone extra testing.

Herpes simplex virus type 1 is linked to Alzheimer disease, although the risk is lower with use of antiherpetics.

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.

Training for those who administer cosmetic injections is lacking, despite significant growth in demand for fillers in the aesthetic medicine industry.

The FDA has ordered Pfizer and Moderna to amend the warning labels on their COVID-19 vaccines with risk of myocarditis and pericarditis.

Patients with varicose veins have a higher risk for all-cause dementia, while treatment of varicose veins is tied to a lower risk for vascular dementia.